Lawrence D. Firestone, President, CEO & Chairman, emphasized the company's leadership in tobacco harm reduction, highlighting the proprietary low nicotine tobacco strains forming the basis of their 95 ...

Esperion Therapeutics remains a buy despite market skepticism, recent stock offering, and underwhelming Q3 earnings, supported by strong cardiovascular drug franchises. ESPR's profitability timeline ...

Management now expects profitability to be achieved in the first half of 2026, later than previously indicated. Otto said, "we now expect the impact of delays in the time necessary to execute the ...